Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Follow-Up Questions
Aligos Therapeutics Inc의 CEO는 누구입니까?
Dr. Lawrence Blatt은 2018부터 회사에 합류한 Aligos Therapeutics Inc의 Chairman of the Board입니다.
ALGS 주식의 가격 성능은 어떻습니까?
ALGS의 현재 가격은 $10.55이며, 전 거래일에 increased 5.6% 하였습니다.
Aligos Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Aligos Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Aligos Therapeutics Inc의 시가총액은 얼마입니까?
Aligos Therapeutics Inc의 현재 시가총액은 $64.8M입니다
Aligos Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Aligos Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 6명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
